Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review.

<h4>Background and aims</h4>Excessive generation of plasminogen activator inhibitor-type 1 (PAI-1) is implicated in the pathogenesis of pre-eclampsia and related conditions. The PAI-1 (-675 4G/5G) promoter polymorphism (rs1799889) affects transcriptional activity and is a putative geneti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jessie A Morgan, Sarah Bombell, William McGuire
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/e88d1687f02b41c38a973a5f04718ee1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e88d1687f02b41c38a973a5f04718ee1
record_format dspace
spelling oai:doaj.org-article:e88d1687f02b41c38a973a5f04718ee12021-11-18T07:57:15ZAssociation of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review.1932-620310.1371/journal.pone.0056907https://doaj.org/article/e88d1687f02b41c38a973a5f04718ee12013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23457639/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background and aims</h4>Excessive generation of plasminogen activator inhibitor-type 1 (PAI-1) is implicated in the pathogenesis of pre-eclampsia and related conditions. The PAI-1 (-675 4G/5G) promoter polymorphism (rs1799889) affects transcriptional activity and is a putative genetic risk factor for pre-eclampsia. The aim of this study was identify, appraise and synthesise the available evidence for the association of the PAI-1 (-675 4G/5G) polymorphism with pre-eclampsia.<h4>Methods</h4>Systematic review and random effects meta-analysis of genetic association studies.<h4>Results</h4>We found 12 eligible genetic association studies in which a total of 1511 women with pre-eclampsia, eclampsia or HELLP syndrome and 3492 controls participated. The studies were generally small (median number of cases 102, range 24 to 403) and underpowered to detect plausible association sizes. Meta-analysis of all of the studies detected statistically significant gene-disease associations in the recessive [pooled odds ratio 1.28 (95% confidence interval 1.09, 1.50); population attributable risk 7.7%] and dominant [pooled odds ratio 1.21 (95% confidence interval 1.01, 1.44); population attributable risk 13.7%] models. We did not find evidence of statistical heterogeneity, funnel plot asymmetry or small study bias.<h4>Conclusions</h4>These data suggest that the fibrinolytic pathway regulated by the PAI-1 gene may contribute to the pathogenesis of pre-eclampsia and related conditions. This association, if confirmed in larger genetic association studies, may inform research efforts to develop novel interventions or help to prioritise therapeutic targets that merit evaluation in randomised clinical trials.Jessie A MorganSarah BombellWilliam McGuirePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 2, p e56907 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Jessie A Morgan
Sarah Bombell
William McGuire
Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review.
description <h4>Background and aims</h4>Excessive generation of plasminogen activator inhibitor-type 1 (PAI-1) is implicated in the pathogenesis of pre-eclampsia and related conditions. The PAI-1 (-675 4G/5G) promoter polymorphism (rs1799889) affects transcriptional activity and is a putative genetic risk factor for pre-eclampsia. The aim of this study was identify, appraise and synthesise the available evidence for the association of the PAI-1 (-675 4G/5G) polymorphism with pre-eclampsia.<h4>Methods</h4>Systematic review and random effects meta-analysis of genetic association studies.<h4>Results</h4>We found 12 eligible genetic association studies in which a total of 1511 women with pre-eclampsia, eclampsia or HELLP syndrome and 3492 controls participated. The studies were generally small (median number of cases 102, range 24 to 403) and underpowered to detect plausible association sizes. Meta-analysis of all of the studies detected statistically significant gene-disease associations in the recessive [pooled odds ratio 1.28 (95% confidence interval 1.09, 1.50); population attributable risk 7.7%] and dominant [pooled odds ratio 1.21 (95% confidence interval 1.01, 1.44); population attributable risk 13.7%] models. We did not find evidence of statistical heterogeneity, funnel plot asymmetry or small study bias.<h4>Conclusions</h4>These data suggest that the fibrinolytic pathway regulated by the PAI-1 gene may contribute to the pathogenesis of pre-eclampsia and related conditions. This association, if confirmed in larger genetic association studies, may inform research efforts to develop novel interventions or help to prioritise therapeutic targets that merit evaluation in randomised clinical trials.
format article
author Jessie A Morgan
Sarah Bombell
William McGuire
author_facet Jessie A Morgan
Sarah Bombell
William McGuire
author_sort Jessie A Morgan
title Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review.
title_short Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review.
title_full Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review.
title_fullStr Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review.
title_full_unstemmed Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review.
title_sort association of plasminogen activator inhibitor-type 1 (-675 4g/5g) polymorphism with pre-eclampsia: systematic review.
publisher Public Library of Science (PLoS)
publishDate 2013
url https://doaj.org/article/e88d1687f02b41c38a973a5f04718ee1
work_keys_str_mv AT jessieamorgan associationofplasminogenactivatorinhibitortype16754g5gpolymorphismwithpreeclampsiasystematicreview
AT sarahbombell associationofplasminogenactivatorinhibitortype16754g5gpolymorphismwithpreeclampsiasystematicreview
AT williammcguire associationofplasminogenactivatorinhibitortype16754g5gpolymorphismwithpreeclampsiasystematicreview
_version_ 1718422764264620032